首页> 外文期刊>Epilepsia Open >Validation of EpiTRAQ, a transition readiness assessment tool for adolescents and young adults with epilepsy
【24h】

Validation of EpiTRAQ, a transition readiness assessment tool for adolescents and young adults with epilepsy

机译:EPITRAQ,青少年和癫痫的年轻成年人的过渡准备评估工具

获取原文
           

摘要

Objective To design and validate a transition readiness assessment tool for adolescents and young adults with epilepsy and without intellectual disability. Methods We adapted a general transition readiness assessment tool (TRAQ) to add epilepsy‐relevant items based on concepts in current epilepsy quality measures. The adapted tool, EpiTRAQ, maintained the original structure and scoring system. Concurrent with clinical implementation in pediatric and adult epilepsy clinics at an academic medical center, we assessed the validity and reliability of this adapted tool for patients 16‐26?years of age. This process included initial validation with 302 patients who completed EpiTRAQ between October 2017 and May 2018; repeat validation with 381 patients who completed EpiTRAQ between June 2018 and September 2019; and retest reliability among 153 patients with more than one completed EpiTRAQ. Results Mean scores were comparable between initial and repeat validation populations (absolute value differences between 0.05 and 0.1); internal consistency ranged from good to high. For both the initial and repeat validation, mean scores and internal consistency demonstrated high comparability to the original TRAQ validation results. Upon retest, few patients rated themselves with a lower score, while the majority rated themselves with higher scores. Significance EpiTRAQ is a valid and reliable tool for assessing transition readiness in adolescents and young adults with epilepsy and without intellectual disability.
机译:目的旨在为癫痫患者和智力残疾的青少年和年轻成人进行转型准备评估工具。方法采用一般转型准备评估工具(TRAQ),基于目前癫痫质量措施的概念添加癫痫相关项目。适应的工具,EPITraq,维持了原始的结构和评分系统。在学术医疗中心的儿科和成人癫痫诊所的临床实施同时,我们评估了16-26岁的患者这种适应工具的有效性和可靠性。该过程包括初始验证,302名患者于2017年10月至2018年5月完成EPITraq;重复验证2018年6月和2019年9月在2019年6月至9月完成EPITRAQ患者;在153名患者中保持可靠性,超过一个完成的EPITRAQ。结果初始和重复验证群之间的分数相当(0.05和0.1之间的绝对值差异);内部一致性范围从良好到高。对于初始和重复验证,平均分数和内部一致性对原始TRAQ验证结果的可比性很高。重新测试后,很少有患者均以较低的分数评定,而大多数评分较高的分数。意义epitraq是一种有效且可靠的工具,用于评估青少年和癫痫和没有智力残疾的青少年和年轻成人的转型含量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号